Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
Rhea-AI Summary
Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026 to review fourth quarter and full year 2025 financial results and provide business updates.
Investors can access the event via the company’s Investor Events page; an archived webcast will be posted on the Wave Life Sciences website after the live event.
Positive
- None.
Negative
- None.
News Market Reaction – WVE
In the Feb 19 session, WVE gained 0.53%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2025-11-10 | Q3 2025 earnings | Neutral | -10.3% | Reported Q3 2025 financials with detailed WVE-007 and WVE-006 data. |
| 2025-11-04 | Earnings call scheduled | Neutral | -3.6% | Announced November 10, 2025 Q3 results webcast and conference call. |
| 2025-07-30 | Q2 2025 earnings | Neutral | -1.9% | Released Q2 2025 results and pipeline progress for key programs. |
| 2025-07-23 | Earnings call scheduled | Neutral | +7.9% | Set July 30, 2025 webcast to discuss Q2 2025 results. |
| 2025-05-08 | Q1 2025 earnings | Neutral | +0.8% | Reported Q1 2025 results and multiple clinical pipeline updates. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-tagged events over the past year showed an average move of -1.43%, suggesting a modestly negative historical bias around financial updates.
Across 2025, Wave Life Sciences delivered a steady cadence of quarterly financial updates paired with clinical progress. Q1–Q3 2025 earnings releases highlighted advancing programs such as WVE-006 for AATD, WVE-007 for obesity, and WVE-N531 and WVE-003 in neuromuscular and CNS indications. Two scheduling releases set expectations for Q2 and Q3 calls. Historically, share reactions to these earnings-related communications have been mixed, with several negative sessions and a few positive days around updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company’s fourth quarter and full year 2025 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
